MA51988A - Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale - Google Patents

Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale

Info

Publication number
MA51988A
MA51988A MA051988A MA51988A MA51988A MA 51988 A MA51988 A MA 51988A MA 051988 A MA051988 A MA 051988A MA 51988 A MA51988 A MA 51988A MA 51988 A MA51988 A MA 51988A
Authority
MA
Morocco
Prior art keywords
preparation
compounds useful
treating spinal
spinal amyotrophy
amyotrophy
Prior art date
Application number
MA051988A
Other languages
English (en)
Inventor
Luke Green
Nikolai A Naryshkin
Hasane Ratni
Marla L Weetall
Original Assignee
Hoffmann La Roche
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA51988(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Ptc Therapeutics Inc filed Critical Hoffmann La Roche
Publication of MA51988A publication Critical patent/MA51988A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051988A 2014-05-15 2015-05-11 Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale MA51988A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15

Publications (1)

Publication Number Publication Date
MA51988A true MA51988A (fr) 2021-01-20

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
MA39995A MA39995B1 (fr) 2014-05-15 2015-05-11 Composés destinés à traiter l'amyotrophie spinale
MA051988A MA51988A (fr) 2014-05-15 2015-05-11 Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA39995A MA39995B1 (fr) 2014-05-15 2015-05-11 Composés destinés à traiter l'amyotrophie spinale

Country Status (36)

Country Link
US (1) US9969754B2 (fr)
EP (3) EP3663296B1 (fr)
JP (1) JP6236173B2 (fr)
KR (2) KR102213740B1 (fr)
CN (1) CN106459092B (fr)
AR (2) AR100442A1 (fr)
AU (1) AU2015261046C1 (fr)
BR (1) BR112016026205B1 (fr)
CA (1) CA2948561C (fr)
CL (1) CL2016002836A1 (fr)
CR (1) CR20160518A (fr)
DK (1) DK3143025T3 (fr)
EA (2) EA035068B1 (fr)
ES (2) ES2949660T3 (fr)
FR (1) FR21C1039I2 (fr)
HR (2) HRP20192159T1 (fr)
HU (2) HUE046491T2 (fr)
IL (2) IL248653B (fr)
LT (1) LTC3143025I2 (fr)
MA (2) MA39995B1 (fr)
MX (1) MX371050B (fr)
MY (1) MY174284A (fr)
NL (1) NL301128I2 (fr)
NO (2) NO2021035I1 (fr)
NZ (1) NZ725008A (fr)
PE (1) PE20170128A1 (fr)
PH (1) PH12016502081B1 (fr)
PL (2) PL3663296T3 (fr)
PT (1) PT3143025T (fr)
RS (1) RS59718B1 (fr)
SG (1) SG11201609497TA (fr)
SI (2) SI3143025T1 (fr)
TW (1) TWI667239B (fr)
UA (1) UA119670C2 (fr)
WO (1) WO2015173181A1 (fr)
ZA (1) ZA201607026B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2812004T3 (en) 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
WO2015024876A2 (fr) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Procédé de criblage
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3298017B1 (fr) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Composés pour le traitement d'une amyotrophie spinale
EP4249472A3 (fr) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Procédés de modulation de l'épissage de l'arn
WO2017081111A1 (fr) * 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Composés pour le traitement de la sclérose latérale amyotrophique
JP6659841B2 (ja) * 2015-11-12 2020-03-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための組成物
WO2017097728A1 (fr) 2015-12-10 2017-06-15 F. Hoffmann-La Roche Ag Dérivés de pipéridine pontés
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
EA201991309A1 (ru) * 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
WO2019005993A1 (fr) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Méthodes de traitement de la maladie de huntington
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
HRP20251594T1 (hr) * 2017-09-22 2026-01-30 F. Hoffmann - La Roche Ag Postupak priprave derivata 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona
KR102761837B1 (ko) * 2017-10-03 2025-02-05 에프. 호프만-라 로슈 아게 척수성 근위축증의 새로운 치료법
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
EP3814345B8 (fr) 2018-06-27 2024-10-30 PTC Therapeutics, Inc. Composés aryl et hétérocycliques pour traiter la maladie de huntington
EP3814360B8 (fr) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Composés hétéroaryl pour traiter la maladie de huntington
BR112020026637A2 (pt) 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
IL319888A (en) 2018-10-19 2025-05-01 Hoffmann La Roche Forms of pyrido[2,1-A]pyrimidin-4-one derivatives, their formulations and process for their preparation
WO2020231977A1 (fr) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Composés pour le traitement de la maladie de huntington
CN113966219A (zh) 2019-06-12 2022-01-21 豪夫迈·罗氏有限公司 Sma的新治疗方法
EP4004003A1 (fr) 2019-07-31 2022-06-01 Teva Pharmaceuticals International GmbH Formes à l'état solide de risdiplam et leurs procédés de préparation
KR20230005210A (ko) * 2020-04-08 2023-01-09 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
WO2022048675A1 (fr) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Forme cristalline du risdiplam, son procédé de préparation et son utilisation
WO2022162107A1 (fr) 2021-02-01 2022-08-04 Sandoz Ag Forme cristalline de risdiplam
BR112023018466A2 (pt) * 2021-03-17 2023-10-10 Hoffmann La Roche Derivados de tiazolopirimidinona
CN116997555A (zh) * 2021-03-17 2023-11-03 豪夫迈·罗氏有限公司 新颖噻吩并嘧啶酮衍生物
WO2022194802A1 (fr) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag Nouveaux dérivés de thiadiazolopyrimidone
CA3210678A1 (fr) * 2021-03-18 2022-09-22 F. Hoffmann-La Roche Ag Nouveau procede
WO2023057404A1 (fr) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Nouvelle administration combinée
CN118005654A (zh) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (fr) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale
US20260098048A1 (en) * 2022-09-26 2026-04-09 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
EP4601651A1 (fr) 2022-10-14 2025-08-20 Genentech, Inc. Méthodes de traitement de l'amyotrophie spinale
CN120530115A (zh) * 2023-01-21 2025-08-22 哈曼菲诺化学有限公司 利司扑兰的制备方法、新型中间体及其制备方法
WO2024218207A1 (fr) 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Dérivés de thiéno[3,2-b]pyridine
WO2024251925A1 (fr) 2023-06-09 2024-12-12 F. Hoffmann-La Roche Ag Système d'expression génique inductible
CN117050096A (zh) * 2023-07-17 2023-11-14 杭州诺澳生物医药科技有限公司 一种利司扑兰的制备方法
US20250144031A1 (en) * 2023-10-27 2025-05-08 Hoffmann-La Roche Inc. Composition for treating spinal muscular atrophy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710808A (pt) * 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
EP2215074B1 (fr) 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Composés d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations
WO2009151546A2 (fr) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Procédés de traitement d'une atrophie musculaire spinale
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
WO2010019243A1 (fr) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc. Méthodes de traitement d’infections virales
EP2337609B1 (fr) * 2008-08-14 2016-08-17 Cardiac Pacemakers, Inc. Évaluation et adaptation des performances d'une liaison de communication acoustique
KR102057351B1 (ko) * 2011-12-30 2019-12-18 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
PL2809322T3 (pl) * 2012-01-26 2019-11-29 Ptc Therapeutics Inc Związki do leczenia zaniku mięśni pochodzenia rdzeniowego
DK2812004T3 (en) * 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
JP6659841B2 (ja) 2015-11-12 2020-03-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための組成物

Also Published As

Publication number Publication date
IL248653A0 (en) 2017-01-31
EA035068B1 (ru) 2020-04-23
PH12016502081A1 (en) 2017-01-09
HRP20230637T1 (hr) 2023-09-29
SI3143025T1 (sl) 2020-01-31
SG11201609497TA (en) 2016-12-29
PE20170128A1 (es) 2017-03-16
FR21C1039I1 (fr) 2021-10-15
EA202090486A2 (ru) 2020-06-30
HRP20192159T1 (hr) 2020-02-21
CN106459092B (zh) 2019-10-15
JP2017515863A (ja) 2017-06-15
CA2948561C (fr) 2019-10-22
AR131260A2 (es) 2025-03-05
EA201692280A1 (ru) 2018-07-31
TW201609738A (zh) 2016-03-16
EP3663296B1 (fr) 2023-05-17
CN106459092A (zh) 2017-02-22
EP3663296A1 (fr) 2020-06-10
IL270027B (en) 2020-08-31
NO2025038I1 (no) 2025-08-14
NL301128I2 (nl) 2021-10-25
FR21C1039I2 (fr) 2022-09-02
EP4241772A2 (fr) 2023-09-13
ES2949660T3 (es) 2023-10-02
IL248653B (en) 2019-11-28
EA202090486A3 (ru) 2020-08-31
BR112016026205B1 (pt) 2021-12-07
EP3143025B1 (fr) 2019-10-09
MX371050B (es) 2020-01-14
ZA201607026B (en) 2022-05-25
AR100442A1 (es) 2016-10-05
SI3663296T1 (sl) 2023-08-31
CL2016002836A1 (es) 2017-04-21
LTC3143025I2 (fr) 2023-11-10
HUE046491T2 (hu) 2020-03-30
CR20160518A (es) 2017-02-21
BR112016026205A2 (pt) 2017-08-15
PT3143025T (pt) 2019-12-03
NL301128I1 (fr) 2021-09-22
US9969754B2 (en) 2018-05-15
CA2948561A1 (fr) 2015-11-19
MY174284A (en) 2020-04-01
LTPA2021010I1 (fr) 2021-10-11
KR20170003687A (ko) 2017-01-09
JP6236173B2 (ja) 2017-11-22
EP4241772A3 (fr) 2023-11-15
KR102213740B1 (ko) 2021-02-09
TWI667239B (zh) 2019-08-01
NO2021035I1 (no) 2021-09-10
AU2015261046A1 (en) 2016-10-27
BR112016026205A8 (pt) 2021-07-20
RS59718B1 (sr) 2020-01-31
WO2015173181A1 (fr) 2015-11-19
HUS2100037I1 (hu) 2021-10-28
DK3143025T3 (da) 2019-12-09
UA119670C2 (uk) 2019-07-25
MA39995B1 (fr) 2019-11-29
PL3663296T3 (pl) 2023-08-07
PH12016502081B1 (en) 2022-11-23
PL3143025T3 (pl) 2020-03-31
ES2761423T3 (es) 2020-05-19
AU2015261046B2 (en) 2019-04-18
MX2016014547A (es) 2017-02-23
NZ725008A (en) 2019-11-29
AU2015261046C1 (en) 2019-07-25
US20170197990A1 (en) 2017-07-13
KR20210014219A (ko) 2021-02-08
KR102256013B1 (ko) 2021-05-26
EP3143025A1 (fr) 2017-03-22

Similar Documents

Publication Publication Date Title
MA51988A (fr) Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale
EP3434645A4 (fr) Procédé de préparation en continu de nanoplaquettes d'oxyde de graphène
EP3013345A4 (fr) Composés pour le traitement d'une amyotrophie spinale
EP3353841A4 (fr) Procédé de préparation et d'application de composites de carbone-sélénium
EP2828247A4 (fr) Composés pour le traitement de l'amyotrophie spinale
EP2819519A4 (fr) Composés pour le traitement de l'amyotrophie spinale
EP3647310A4 (fr) Procédé de préparation de 2,5-furandiméthylcarboxylate à partir d'hydroxyméthylfurfural
EP3706725A4 (fr) Processus pour la préparation de tapinarof
MA43099A (fr) Procédé pour la préparation de chlorure de vinyle
EP3383436A4 (fr) Procédé amélioré de préparation de vert d'indocyanine
EP3695433A4 (fr) Procédé de préparation d'échantillon de section transversale
MA55917A (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
EP3341359A4 (fr) Procédé de préparation d'aprémilast
EP3766869A4 (fr) Procédé simple de préparation d'avibactam
MA42423A (fr) Procédé de préparation d'un revêtement
EP3500551A4 (fr) Procédé de préparation de biphényles substitués
EP3696168A4 (fr) Procédé de préparation de 2-chloro-5-trifluorométhylpyridine
EP3511313A4 (fr) Procédé de préparation de 1,3-cyclohexanediméthanol
MA51870A (fr) Procédé pour la préparation de composés coupleurs de médicaments
EP3505525A4 (fr) Procédé de préparation de rubusoside
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
EP3311804A4 (fr) Procédé d'élaboration de microcapsules de type colloïdosome
EP3666756A4 (fr) Procédé de préparation de lévétiracétam
EP3533856A4 (fr) Procédé de préparation d'hexadécahydropyrène
EP3733651A4 (fr) Procédé de préparation de calcobutrol